Lineage Cell Therapeutics Inc Revenue Growth Rates (LCTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lineage Cell Therapeutics Inc   (NYSE: LCTX)
 

LCTX's Revenue Growth by Quarter and Year

Lineage Cell Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LCTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.07
1st Quarter March 1.73
FY 2.80

LCTXs Annual Revenue
Lineage Cell Therapeutics Inc 's Revenue in the fiscal year 2025 $ 14.56 millions
Lineage Cell Therapeutics Inc 's Revenue in the fiscal year 2024 $ 9.50 millions
Lineage Cell Therapeutics Inc 's Revenue in the fiscal year 2023 $ 8.95 millions
Lineage Cell Therapeutics Inc 's Revenue in the fiscal year 2022 $ 14.70 millions
Lineage Cell Therapeutics Inc 's Revenue in the fiscal year 2021 $ 4.34 millions




LCTX Revenue second quarter 2026 Y/Y Growth Comment
Lineage Cell Therapeutics Inc reported drop in Revenue in the second quarter 2026 by -61.41% to $ 1.07 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Lineage Cell Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 32.72%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Lineage Cell Therapeutics Inc ' s Revenue meltdown of -61.41% ranks overall at the positon no. 1159 in the second quarter 2026.


LCTX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 130.31 % 37.32 % 8.85 %
3rd Quarter September - -2.65 % 202.4 % -58.33 %
2nd Quarter June -61.41 % 96.45 % -56.35 % -29.01 %
1st Quarter March 15.33 % 4.17 % -39.75 % -54.39 %
FY   - 53.26 % 6.03 % -

Financial Statements
Lineage Cell Therapeutics Inc 's second quarter 2026 Revenue $ 1.07 millions LCTX's Income Statement
Lineage Cell Therapeutics Inc 's second quarter 2025 Revenue $ 2.77 millions Quarterly LCTX's Income Statement


LCTX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 79.62 % -24.07 % 67.2 %
3rd Quarter September - 32.85 % 168.09 % -61.3 %
2nd Quarter June -38.21 % 84.67 % -2.08 % 35.15 %
1st Quarter March -73.83 % -47.74 % -31.1 % 24.48 %
FY (Year on Year)   - 53.26 % 6.03 % -


Back to LCTX Growth rate Comparisons >> Back to LCTX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #211
Overall #1159

Revenue Y/Y Growth Statistics
High Average Low
623.24 % 32.72 % -51.51 %
(Jun 30 2022)   (Jun 30 2017)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #211
Overall #1159
Revenue Y/Y Growth Statistics
High Average Low
623.24 % 32.72 % -51.51 %
(Jun 30 2022)   (Jun 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lineage Cell Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
348.37 % 24.47 % -73.9 %
(Mar 31 2022)  


LCTX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Lineage Cell Therapeutics Inc disclosed fall in Revenue from the first quarter by -38.21% to $ 1.07 millions, from $ 1.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Lineage Cell Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3570.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #502
Overall #3570
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #502
Overall #3570
Revenue Q/Q Growth Statistics
High Average Low
348.37 % 24.47 % -73.9 %
(Mar 31 2022)  


LCTX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Lineage Cell Therapeutics Inc disclosed fall in Revenue from the first quarter by -38.21% to $ 1.07 millions, from $ 1.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Lineage Cell Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3570.


Lineage Cell Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 13.08 $ 14.78 $ 14.56 $ 10.82 $ 10.91
Y / Y Revenue Growth (TTM) 19.87 % 54.64 % 53.24 % 24.05 % 76.43 %
Year on Year Revenue Growth Overall Ranking # 218 # 706 # 1392 # 1601 # 3042
Seqeuential Revenue Change (TTM) -11.48 % 1.53 % 34.58 % -0.9 % 14.2 %
Seq. Revenue Growth (TTM) Overall Ranking # 1159 # 2399 # 1127 # 175 # 2970


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Lineage Cell Therapeutics Inc 's cumulative twelve months Revenue were $ 13 millions, company would post below average annual Revenue growth of 14.2% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Lineage Cell Therapeutics Inc 's Revenue growth from the 1.73% growth in Mar 31 2026.

In the Healthcare sector 60 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 218, from total ranking in previous quarter at 706.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 61
Overall # 218

Revenue TTM Y/Y Growth Statistics
High Average Low
623.24 %
 32.72 %
-51.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 211
S&P 500 # 1159
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Lineage Cell Therapeutics Inc 's cumulative twelve months Revenue were $ 13 millions, company would post below average annual Revenue growth of -51.51% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Lineage Cell Therapeutics Inc 's Revenue growth from the 1.73% growth in Mar 31 2026.

In the Healthcare sector 60 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 218, from total ranking in previous quarter at 706.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 61
Overall # 218

Revenue TTM Y/Y Growth Statistics
High Average Low
623.24 %
32.72 %
-51.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 211
S&P 500 # 1159




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LCTX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Lineage Cell Therapeutics Inc Revenue Growth Rates (LCTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lineage Cell Therapeutics Inc (CIK 876343).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-338064
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lineage Cell Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.